Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK statement in response to the Prime Minister’s speech on life sciences
The Government's strategy for Life Sciences is an important step to make UK the best place in the world to locate pharmaceutical investment.
-
Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine
GSK submitted information to the FDA supporting BLA for combination vaccine MenHibrix. submitted in response to Complete Response letter.
-
Reporting on a core earnings basis will begin with effect from Q1 2012
Go to the Presentations and webcasts page for the full announcement.
-
GSK welcomes GAVI Alliance decision to introduce vaccines against cervical cancer and rubella in the world’s poorest countries
GAVI Board to provide funding for cervical cancer immunisation programmes & rubella vaccination, across the world's poorest countries.
-
GlaxoSmithKline welcomes innovative knowledge-sharing collaboration to break deadlock in antibiotic discovery and development
GSK welcomes EC decision to promote collaborative research efforts to develop new antibiotics against growing threat from resistant bacteria
-
GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes
Head-to-head study primary end point did not meet non-inferiority, but results support progression towards registration
-
Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix® (HPV 16 and 18 vaccine) against precancerous cervical lesions
Analysis in TheLancet reinforces findings that GSK's Cervarix, provided protection against CIN3+, above expected from a vaccine against HPV.
-
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia
Full results from ENABLE 1 & 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases
-
GlaxoSmithKline reaches agreement in principle to resolve multiple investigations with US Government
GSK announced it's reached an agreement with US Gov to conclude the Company’s most significant ongoing Federal government investigations
-
GSK delivers strong Q3 performance with underlying sales growth of 6% and reported sales growth of 3%
Full details of GSK's results for the third quarter of 2011 can be found in the Investors section of GSK.com.
-
GSK joins WIPO Re:Search open innovation platform as part of its commitment to tackling diseases of the developing world
GSK joined WIPO Re:Search in innovation strategy to help accelerate the development of treatments of NTDs affecting over a billion each year
-
First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months
Half the world's population at risk of malaria responsible for 800,000 deaths each year, most of whom children under 5 in sub-Saharan Africa
-
Regulatory Update: GlaxoSmithKline receives Complete Response letter from FDA for candidate meningococcal and Hib combination vaccine
GSK announced it's received a Complete Response letter from FDA for MenHibrix ,active immunization of infants 6 weeks through 15 months
-
Lucozade to help drive Vodafone McLaren Mercedes performance
Ahead of Singapore Grand Prix, Lucozade announces an innovative performance partnership with the Vodafone McLaren Mercedes Formula 1 team.
-
GlaxoSmithKline (GSK) and McLaren Group announce innovative strategic partnership
GSK announced it's formed a partnership with McLaren Group which will run initially until 2016 focusing on innovation and high-tech research
-
GlaxoSmithKline (GSK) commits $1 million in cervical cancer vaccine to new cooperative effort aimed at reducing deaths from women's cancers
GSK has committed $1 million in Cervarix, cervical cancer vaccine to the Pink Ribbon Red Ribbon partnership over the next five years.
-
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
-
GSK gives update on agreement with World Health Organization to support de-worming of school age children in endemic countries
First African countries, Togo and Rwanda, receive albendazole donations to scale-up school based de-worming programmes for children at risk.
-
Lapatinib clinical trial update
Review - Phase III study of lapatinib & trastuzumab in patients with HER2+ early stage breast cancer to continue trials without modification
-
Jens Eckstein named President of SR One, GSK’s venture healthcare group
Jens Eckstein has been named President of SR One, GSK's independent healthcare venture organisation, effective 1 October.